This article was originally published in The Tan Sheet
Combination glucosamine/chondroitin sulfate "is effective in treating moderate to severe knee pain due to osteoarthritis," Daniel Clegg, University of Utah, et al., conclude in the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Findings will be presented at the American College of Rheumatology annual meeting in San Diego, Calif. Nov. 14. Authors evaluated 1,583 patients age 40 and older with knee pain of at least six months duration. Participants were randomized to either glucosamine, chondroitin, a glucosamine/chondroitin combination, celecoxib (Pfizer's Celebrex) or placebo for 24 weeks. Authors used WOMAC pain scores to determine the amount of relief experienced by each patient...
You may also be interested in...
Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?